Related Experiment Video
Updated: Aug 14, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
Published on: March 21, 2025
Thoratec ventricular assist devices in pediatric patients: update on clinical results
Olaf Reinhartz1, J Donald Hill, Abdulaziz Al-Khaldi
1Stanford University, Department of Cardiothoracic Surgery, 300 Pasteur Drive, Stanford, CA 94605, USA.
Insights
Mechanical circulatory support using Thoratec ventricular assist devices (VAD) in pediatric patients shows a 68% survival rate. Survival is lower for congenital heart disease patients, especially in smaller children.
Area of Science:
- Pediatric cardiology
- Mechanical circulatory support
- Cardiothoracic surgery
Background:
- Mechanical circulatory support (MCS) in pediatric patients presents unique clinical challenges.
- The Thoratec ventricular assist device (VAD) is a key technology in pediatric MCS.
Purpose of the Study:
- To analyze the Stanford experience and worldwide data on Thoratec VAD use in pediatric and adolescent patients.
- To evaluate survival rates and identify factors influencing outcomes in this population.
Main Methods:
- Retrospective analysis of 209 pediatric patients (age 5-18) who received Thoratec VAD support up to January 2005.
- Data included patient demographics, primary diagnosis, duration of support, and survival outcomes.
- Subanalysis of small children (body surface area < 1.3 m2) was performed.
Main Results:
- Overall survival to transplantation or device explantation was 68%.
- Higher survival rates were observed for cardiomyopathies (74%) and acute myocarditis (86%) compared to congenital heart disease (27%).
- Small children (< 1.3 m2 BSA) had a higher incidence of congenital heart disease and lower survival (52%).
Conclusions:
- Thoratec VAD support offers a survival benefit in pediatric patients, particularly for cardiomyopathies and myocarditis.
- Congenital heart disease remains a significant challenge, with poorer outcomes in smaller pediatric patients.
- Specific management strategies are crucial for optimizing outcomes in small children requiring VAD support.
Abstract:
Particularly in pediatric patients, mechanical circulatory support remains a clinical challenge. We analyzed the Stanford experience with use of the Thoratec ventricular assist device (VAD) in children and adolescents and data from the company's voluntary database. Through January 2005, 209 patients up to 18 years of age have been supported with the Thoratec VAD worldwide. Mean age was 14.5 years (range 5-18 years), mean weight was 57 kg (range 17-118 kg), and mean body surface area was 1.6 m2 (range 0.7-2.3 m2). The majority of patients were supported for cardiomyopathies (55%) and acute myocarditis (25%). A minority (6%) was treated for end-stage congenital heart disease. Average duration of support was 44 days (0-434 days). Overall survival to transplantation or weaning off the device was 68%. Survival rates were higher for patients with cardiomyopathies (74%) and acute myocarditis (86%) compared with patients with congenital heart disease (27%). We performed a subanalysis in small children with a body surface area of less 1.3 m2. This subgroup had a higher incidence of congenital heart disease and a slightly lower survival (52%). Aspects of the particular risks and device management in these small patients are discussed.
Related Concept Videos
Mechanical Ventilation III: Noninvasive Ventilation
Noninvasive Positive-Pressure Ventilation (NIPPV)
Mechanical Ventilation II: Invasive Ventilation
Negative-Pressure Ventilators
Negative-pressure ventilators create a vacuum around the chest or body to draw air into the lungs, simulating breathing. This method does not require an...
Cardiomyopathy V: Interprofessional Care
Mitral Stenosis III: Medical Management
